Cleveland BioLabs dives after BARDA ends negotiations to back radiation drug
This article was originally published in Scrip
Executive Summary
Cleveland BioLabs (CBLI) had a rough ride on Wall Street on 23 January, with shares diving 44% in morning trading, after the company revealed the US Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services, had terminated the negotiations on the biotech's proposal for further development of its investigational acute radiation syndrome agent entolimod (CBLB502) as a medical countermeasure (MCM).